UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bayesian Statistics and Marketing

1. Aufl., 2012

Volltextzugriff (PDF)

Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: The 20030125 Study Group Trial

Journal of clinical oncology, 2006-05, Vol.24 (15), p.2290-2297

2006

Volltextzugriff (PDF)

Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): Searching for Standards

Journal of pain and symptom management, 2010-06, Vol.39 (6), p.1077-1085

2010

Volltextzugriff (PDF)

What principles should govern the use of managed entry agreements?

International journal of technology assessment in health care, 2011-01, Vol.27 (1), p.77-83

2011

Volltextzugriff (PDF)

Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa

European journal of cancer (1990), 2005-05, Vol.41 (8), p.1140-1149

2005

Volltextzugriff (PDF)

Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy‐induced anemia

Cancer, 2007-10, Vol.110 (7), p.1629-1640

2007

Volltextzugriff (PDF)

Author reply

Cancer, 2004-04, Vol.100 (7), p.1546-1546

2004

Volltextzugriff (PDF)

Author reply

Cancer, 2004-04, Vol.100 (7), p.1546-1546

2004

Volltextzugriff (PDF)

A Randomized Comparison of Every‐2‐Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy‐Induced Anemia in Patients With Breast, Lung, or Gynecologic Cancer

The oncologist (Dayton, Ohio), 2004-01, Vol.9 (6), p.696-707

2004

Volltextzugriff (PDF)

Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia : Results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-α at a dose of 200 μg every 2 weeks

Cancer, 2007-10, Vol.110 (7), p.1629-1640

2007

Volltextzugriff (PDF)

Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia

JNCI : Journal of the National Cancer Institute, 2006-02, Vol.98 (4), p.273-284

2006

Volltextzugriff (PDF)

Efficacy and Safety of Every‐2‐Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open‐Label Phase II Trial

The oncologist (Dayton, Ohio), 2007-06, Vol.12 (6), p.727-737

2007

Volltextzugriff (PDF)

A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia

Clinical therapeutics, 2003-11, Vol.25 (11), p.2781-2796

2003

Volltextzugriff (PDF)

Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks

Cancer, 2007-10, Vol.110 (7), p.1629

2007

Volltextzugriff (PDF)

Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia

Pediatric blood & cancer, 2007-10, Vol.49 (5), p.687-693

2007

Volltextzugriff (PDF)

A Randomized, Open‐Label, Multicenter Trial of Immediate Versus Delayed Intervention with Darbepoetin Alfa for Chemotherapy‐Induced Anemia

The oncologist (Dayton, Ohio), 2007-10, Vol.12 (10), p.1253-1263

2007

Volltextzugriff (PDF)

Effectiveness of Darbepoetin alfa Administered Every 3 Weeks on Clinical Outcomes in Patients with Hematologic Malignancies and Chemotherapy-Induced Anemia

Blood, 2005-11, Vol.106 (11), p.3767-3767

2005

Volltextzugriff (PDF)

Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy

Clinical pharmacokinetics, 2006-01, Vol.45 (2), p.199-211

2006

Volltextzugriff (PDF)

Treatment of Chemotherapy-Induced Anemia in Breast Cancer: Results of a Randomized Controlled Trial of Darbepoetin Alfa 200 μg Every 2 Weeks Versus Epoetin Alfa 40,000 U Weekly

Clinical breast cancer, 2005, Vol.6 (5), p.446-454

2005

Volltextzugriff (PDF)

Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia

Blood, 2005-11, Vol.106 (11), p.3556-3556

2005

Volltextzugriff (PDF)

A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia

Current medical research and opinion, 2007-06, Vol.23 (6), p.1387-1401

2007

Volltextzugriff (PDF)

An Evaluation of the Effectiveness of Darbepoetin alfa 300 mcg Every 3 Weeks (Q3W) on Clinical Outcomesin Cancer Patients with Chemotherapy-Induced Anemia

Blood, 2004-11, Vol.104 (11), p.5310-5310

2004

Volltextzugriff (PDF)

A randomized, active‐control, pilot trial of front‐loaded dosing regimens of darbepoetin‐alfa for the treatment of patients with anemia during chemotherapy for malignant disease

Cancer, 2004-04, Vol.100 (7), p.1545-1546

Waltzman, Roger J.

2004

Volltextzugriff (PDF)

Efficacy of Darbepoetin Alfa in the Treatment of Chemotherapy-Induced Anemia in Non-Hodgkin's Lymphoma

Blood, 2004-11, Vol.104 (11), p.3296-3296

2004

Volltextzugriff (PDF)

A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome

The Journal of supportive oncology, 2005-11, Vol.3 (6), p.419-426

2005

Volltextzugriff (PDF)

1 – 25 von 137

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(117)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(137)

Erscheinungsjahr

n.n

Thema

Science & Technology
(62)
Life Sciences & Biomedicine
(40)
Humans
(32)
Marketing
(23)
Mathematics
(23)
Physical Sciences
(22)
Male
(21)
Female
(19)
Business & Economics
(18)
Social Sciences
(17)
Middle Aged
(16)
Statistics & Probability
(15)
Aged
(14)
Darbepoetin Alfa
(14)
Erythropoietin - Analogs & Derivatives
(14)
Oncology
(14)
Business
(12)
Erythropoietin - Administration & Dosage
(11)
Treatment Outcome
(11)
Biological And Medical Sciences
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Ssrn Electronic Journal
(10)
Marketing Science
(7)
Cancer
(6)
Journal Of Econometrics
(5)
Blood
(4)
Journal Of The American Statistical Association
(4)
Arthroscopy
(3)
Journal Of Marketing Research
(3)
The Oncologist
(3)
The oncologist
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Bayesian Statistics and Marketing

Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: The 20030125 Study Group Trial

Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): Searching for Standards

What principles should govern the use of managed entry agreements?

Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa

Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy‐induced anemia

Author reply

Author reply

A Randomized Comparison of Every‐2‐Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy‐Induced Anemia in Patients With Breast, Lung, or Gynecologic Cancer

Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia : Results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-α at a dose of 200 μg every 2 weeks

Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia

Efficacy and Safety of Every‐2‐Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open‐Label Phase II Trial

A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia

Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks

Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia

A Randomized, Open‐Label, Multicenter Trial of Immediate Versus Delayed Intervention with Darbepoetin Alfa for Chemotherapy‐Induced Anemia

Effectiveness of Darbepoetin alfa Administered Every 3 Weeks on Clinical Outcomes in Patients with Hematologic Malignancies and Chemotherapy-Induced Anemia

Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy

Treatment of Chemotherapy-Induced Anemia in Breast Cancer: Results of a Randomized Controlled Trial of Darbepoetin Alfa 200 μg Every 2 Weeks Versus Epoetin Alfa 40,000 U Weekly

Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia

A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia

An Evaluation of the Effectiveness of Darbepoetin alfa 300 mcg Every 3 Weeks (Q3W) on Clinical Outcomesin Cancer Patients with Chemotherapy-Induced Anemia

A randomized, active‐control, pilot trial of front‐loaded dosing regimens of darbepoetin‐alfa for the treatment of patients with anemia during chemotherapy for malignant disease

Efficacy of Darbepoetin Alfa in the Treatment of Chemotherapy-Induced Anemia in Non-Hodgkin's Lymphoma

A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome

Suchergebnisse filtern